Once-weekly subcutaneous tirzepatide may not raise risk for depression compared with placebo, according to a post hoc analysis of the SURMOUNT trials. As Healio previously reported, in January the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results